Peptide having cancer selective translocation function and use thereof
US-2015165060-A1 · Jun 18, 2015 · US
Peptide having cancer selective translocation function and use thereof
US9849190B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9849190-B2 |
| Application number | US-201615234396-A |
| Country | US |
| Kind code | B2 |
| Filing date | Aug 11, 2016 |
| Priority date | Sep 18, 2012 |
| Publication date | Dec 26, 2017 |
| Grant date | Dec 26, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
A method of treating breast cancer is described, in which a peptide having cancer selective translocation function-doxoribicin conjugate is administered. The conjugate includes doxorubicin chemically linked to the N-terminus or C-terminus of a VEGF-binding protein transduction domain (VPTD) peptide represented as SEQ ID NO: 1 , wherein the VPTD peptide and doxorubicin are linked to each other by a disulfide bond, and wherein the VPTD peptide binds specifically to vascular endothelial growth factor (VEGF) in tumor cells or tumor tissues.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method of treating a breast cancer, said method comprising a step of administering a peptide having cancer selective translocation function-doxorubicin conjugate, which comprises doxorubicin chemically linked to the N-terminus or C-terminus of VEGF-binding protein transduction domain (VPTD) peptide represented as SEQ ID NO: 1, wherein the VPTD peptide represented as SEQ ID NO: 1 and doxorubicin are linked to each other by a disulfide bond, and wherein the VPTD peptide represented as SEQ ID NO: 1 binds specifically to vascular endothelial growth factor (VEGF) in tumor cells or tumor tissues. 2. The method of claim 1 , wherein doxorubicin and the VPTD peptide are chemically linked by any one crosslinking agent selected from the group consisting of 1,4-bis-maleimidobutane (BMB), 1,11-bis-maleimidotetraethyleneglycol (BM[PEO]4), 1-ethyl-3-[3-dimethyl aminopropyl] carbodiimide hydrochloride (EDC), succinimidyl-4[N-maleimidomethylcyclohexane-1-carboxy-[6 amidocaproate]] (SMCC) and its sulfonate (sulfo-SMCC), succimidyl 6-[3-(2-pyridyldithio) ropionamido] hexanoate (SPDP) and its sulfonate (sulfo-SPDP), m-maleimidobenzoyl-Nhydroxysuccinimide ester (MBS) and its sulfonate (sulfo-MBS), and succimidyl[4-(pmaleimidophenyl) butyrate] (SMPB) and its sulfonate (sulfo-SMPB).
Assignees
Inventors
Classifications
Peptides, proteins, polyamino acids · CPC title
from mammals · CPC title
having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68) · CPC title
involving oxidoreductase · CPC title
containing a tag for extracellular membrane crossing, e.g. TAT or VP22 · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9849190B2 cover?
- A method of treating breast cancer is described, in which a peptide having cancer selective translocation function-doxoribicin conjugate is administered. The conjugate includes doxorubicin chemically linked to the N-terminus or C-terminus of a VEGF-binding protein transduction domain (VPTD) peptide represented as SEQ ID NO: 1 , wherein the VPTD peptide and doxorubicin are linked to each other …
- Who is the assignee on this patent?
- Snu R&Db Foundation, Nano Intelligent Biomedical Eng Corporation Co Ltd, Nano Intelligent Biomedical Eng Corporation Co Ltd
- What technology area does this patent fall under?
- Primary CPC classification C07K14/435. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Dec 26 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).